Roivant Sciences (ROIV) Non-Current Deffered Revenue (2022)
Roivant Sciences' (ROIV) quarterly Non-Current Deffered Revenue came in at $11.9 million in Q3 2022, down 9.47% on a QoQ basis from $13.1 million in Q2 2022.
Roivant Sciences (ROIV) Non-Current Deffered Revenue (2022) Analysis & Trends
Roivant Sciences (ROIV) has 1 years of Non-Current Deffered Revenue data on file, last reported at $11.9 million in Q3 2022.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $11.9 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $11.9 million (changed N/A YoY) and the FY2022 annual result came in at $13.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue fell to $11.9 million in Q3 2022, from $13.1 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $13.7 million in Q1 2022 to a low of $11.9 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 11.90 Mn |
| Jun 30, 2022 | 13.15 Mn |
| Mar 31, 2022 | 13.74 Mn |